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http://dx.doi.org/10.1016/j.ccr.2014.06.026SUMMARYOncoproteins and tumor suppressors antagonistically converge on critical nodes governing neoplastic
growth, invasion, and metastasis. We discovered that phosphorylation of the ETS1 and ETS2 transcriptional
oncoproteins at specific serine or threonine residues creates binding sites for the COP1 tumor suppressor
protein, which is an ubiquitin ligase component, leading to their destruction. In the case of ETS1, however,
phosphorylation of a neighboring tyrosine residue by Src family kinases disrupts COP1 binding, thereby sta-
bilizing ETS1. Src-dependent accumulation of ETS1 in breast cancer cells promotes anchorage-independent
growth in vitro and tumor growth in vivo. These findings expand the list of potential COP1 substrates to
include proteins whose COP1-binding sites are subject to regulatory phosphorylation and provide insights
into transformation by Src family kinases.INTRODUCTION
Regulation of protein stability by ubiquitin ligase complexes
plays an important role in cellular homeostasis including the con-
trol of cancer-relevant processes such as proliferation, differen-
tiation, apoptosis, and angiogenesis. Accordingly, there are now
many examples of driver mutations that alter the behavior of
ubiquitin ligase complexes through alterations of their substrate
recognition subunits. Examples include amplification of MDM2
and SKP2 and mutational inactivation of VHL, FBW7, CBL, and
RFWD2 (COP1) (Lipkowitz and Weissman, 2011).Significance
The COP1 ubiquitin ligase complex is lost in some cancers. It i
stand howCOP1 activity is regulated.Wediscovered that the ET
strates, but only after they are phosphorylated on specific serin
acid residues in the canonical COP1 substrates identified to da
adjacent to its COP1-binding site by Src family kinases allows
the universe of potential COP1 substrates, illustrate how kinas
COP1, and provide additional insights into cellular transforma
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and is deleted in some acute lymphoblastic lymphomas, mela-
nomas, and prostate cancers (Marine, 2012). Deletion of Cop1
in mice causes lymphoma and, when combined with Pten loss,
promotes the development of invasive prostatic cancer (Miglior-
ini et al., 2011; Vitari et al., 2011). The COP1 gene product,
COP1, is the substrate recognition module of an Skp1/Cullin/
F-box (SCF)-type E3 ubiquitin ligase complex that also contains
DET1, DDB4, CUL4A, and RBX1 (Marine, 2012; Wei and Kaelin,
2011). A number of potential COP1 substrates have been identi-
fied including c-Jun family members; the ETS family memberss therefore critical to identify COP1 substrates and to under-
S1 andETS2 oncogenic transcription factors are COP1 sub-
e or threonine residues occupied by aspartic acid or glutamic
te. Moreover, phosphorylation of a tyrosine residue in ETS1
ETS1 to escape recognition by COP1. These studies expand
es can positively or negatively affect degrons recognized by
tion by Src.
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Regulation of ETS1 by Src Family Kinases and COP1ETV1, ETV4, and ETV5; the transcription factor FOXO1; the
metabolic regulators ACC1 and TORC2; and the p53 tumor
suppressor protein (Marine, 2012; Wei and Kaelin, 2011).
Ubiquitin ligases often respond to signals that influence their
catalytic activity or ability to engage substrates. For example,
substrate recognition by SKP2 is linked to substrate phosphory-
lation (Carrano et al., 1999; Sutterlu¨ty et al., 1999; Tsvetkov et al.,
1999) and by pVHL to substrate hydroxylation (Ivan et al., 2001;
Jaakkola et al., 2001). Oncogene activation leads to the induc-
tion of ARF, which physically associates with MDM2 and pre-
vents it from polyubiquitylating p53 (Matheu et al., 2008; Sherr,
2006). In summary, upstream signals are often integrated by
ubiquitin ligases and transduced into changes in substrate
stability.
The viral homolog (v-Src) of the cellular gene SRC played a
pivotal role in the discovery of cellular oncogenes. The Src pro-
tein is a nonreceptor tyrosine kinase that has membrane-associ-
ated, cytosolic, and nuclear targets (Mayer and Krop, 2010;
Summy and Gallick, 2003). Other members of the Src family
include Yes, Fyn, Fgr, Lck, Hck, Blk, and Frk. SRC is overex-
pressed in a variety of tumors and, inmodel systems, contributes
to several hallmarks of cancer including mitogen-indepen-
dent growth, invasion, and metastasis (Mayer and Krop, 2010;
Summy and Gallick, 2003). How, mechanistically, Src family ki-
nases promote transformation is still incompletely understood.
RESULTS
Polyubiquitylation of ETS2 by COP1
To identify COP1 substrates, we infected HCT116 colorectal
cancer cells with a lentivirus encoding FLAG-hemagglutinin
(HA)-COP1, which was then recovered and purified by sequen-
tial anti-FLAG and anti-HA immunopurifications. Bound proteins
were eluted with FLAG and HA peptides, respectively. Proteins
in the HA eluates were precipitated with trichloroacetic acid
and identified by mass spectrometry. Aliquots of the eluates
and flowthroughswere also analyzed bySDS-polyacrylamide gel
electrophoresis followed by silver staining (Figure 1A). Parental
HCT116 cells were similarly processed in parallel as negative
controls.
Using this approach, we detected a number of proteins that
associate with COP1, including components of the core COP1
ubiquitin ligase complex, such as DET1, DDB1, and DDA1, as
well as proteins believed to regulate COP1 function, such as
MVP and TRIB1 (Figure 1B). In addition, we detected the known
COP1 substrate JunB, as well as multiple ETS family members,
including ETV1, ETV4, ETV5, and ETS2 (Figure 1B). Recovery of
the core COP1 ligase complex components Cul4A, DDB1, DET1,
together with ETV5, ETS2, and the canonical COP1 substrate
c-Jun, was confirmed by western blot analysis (Figure 1C).
While this work was in progress, Dixit and coworkers reported
that ETV1, ETV4, and ETV5 are polyubiquitylated by COP1 (Vitari
et al., 2011). We therefore focused our attention on ETS2. ETS2
contains two colinear sequences loosely conforming with the
COP1 degron motif (D/E)-(D/E)-(X)-X-X-V-P-(D/E) (Figure 1D
and Figures S1A and S1B available online). We noticed that in
these two putative degrons, several positions that are normally
occupied by aspartic acid or glutamic acid are instead occupied
by serine or threonine. These ETS2 residues, however, if phos-phorylated, would supply the negative charges normally pro-
vided by aspartic acid or glutamic acid. In fact, ETS2 Ser310
has been reported to be phosphorylated by Ca(2+)/calmodulin-
dependent kinase 2 (CaMKII) (Figure S1C) (Yu et al., 2009),
and we confirmed this phosphorylation event in 293FT human
embryonic kidney cells under basal conditions (Figure S1D).
We therefore transiently transfected 293FT cells with a
plasmid encoding wild-type ETS2-HA or ETS2-HA variants in
which the valine-proline (VP) residues of either the N-terminal
(VPAA1) or C-terminal (VPAA2) motifs were replaced with ala-
nines, respectively. The abundance of wild-type ETS2, as well
as the VPAA1 and VPAA2 variants, were diminished in cells
cotransfected to overproduce COP1 and its partner DET, but
increased in cells cotransfected to produce a dominant-negative
version of COP1 (COP1DE7) (Savio et al., 2008) and DET1 (Fig-
ure 1D). In contrast, the abundance of the ETS2 variant lacking
both motifs (VPAA1&2) was unaffected by COP1 (Figure 1D).
In a complementary set of experiments, we infected 293FT
cells with a lentivirus encoding a doxycycline (DOX)-inducible
shRNA against COP1 and then superinfected these cells with a
lentivirus encoding the HA-tagged ETS2 variants described
above under the control of a weak (Ubc) promoter (Qin et al.,
2010). Wild-type ETS2, VPAA1, and VPAA2 coimmunoprecipi-
tated with COP1 (see Figure 2D below) and were produced at
low levels that were increased upon the administration of DOX
(loss of COP1) (Figure 1E). In contrast, binding of VPAA1&2 to
COP1 was undetectable (see Figure 2D below), and the basal
level of VPAA1&2, which was higher than that of wild-type
ETS2, was not increased further byDOX (Figure 1E). The different
behavior of wild-type ETS2 and VPAA1&2 in these assays was
mirrored by changes in their stability in the presence or absence
ofCOP1 (FigureS1E).Moreover, COP1promoted thepolyubiqui-
tylation of ETS2, but not VPAA1&2, both in vitro (Figure 1F) and
in vivo (Figures 1G and S1F). Collectively, these results indicate
that ETS2, like other ETS family members, is a COP1 substrate.
Tyrosine Phosphorylation Prevents the Recognition of
ETS1 by COP1
We noticed that the ETS2 paralog ETS1 contains a colinear
sequence that is very similar to the C-terminal COP1 degron
we identified in ETS2, and that this sequence, like its ETS2 coun-
terpart, is invariant across a number of mammals, including
rodents (Figures 2A, 2B, and S1A). Furthermore, Ser282 in
ETS1 is, like its counterpart in ETS2 (Ser310), phosphorylated
by CaMKII (Figure S2A) (Cowley and Graves, 2000; Rabault
and Ghysdael, 1994). As predicted from this knowledge, COP1
promoted the polyubiquitylation of wild-type ETS1, but not an
ETS1 variant in which the canonical VP residues within this puta-
tive degronwere converted to alanines (ETS1 VPAA), in vitro (Fig-
ure 2C). Unexpectedly however, ETS1, in contrast to ETS2, did
not bind to COP1 in vivo (Figure 2D) and was not stabilized in
cells upon COP1 loss (Figure 2E). Note that in Figure 2D the cells
were pretreated with carbobenzoxy-L-leucyl-L-leucyl-L-leucinal
(MG132) to facilitate the detection of the COP1-ETS complexes.
We reasoned that this paradoxmight relate to the replacement
of the phenylalanine residue in the ETS2 sequence with a tyro-
sine residue (Tyr283) in the ETS1 sequence, which others have
reported (Mayya et al., 2009), and we confirmed, is phosphory-
lated in vivo (Figures S2A–S2D), and that phosphotyrosine mightCancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc. 223
Figure 1. ETS2 Is a COP1 Substrate
(A) Silver stained gel of proteins recovered after sequential immunoprecipitation (anti-FLAG followed by anti-HA) of cell extracts prepared fromHCT116 colorectal
cancer cells (parental or producing FLAG-HA-COP1). Proteins captured with the anti-FLAG antibody were eluted with Flag peptide (FLAG eluate) and applied to
an anti-HA column, followed by elution with HA peptide (HA eluate). Shown are proteins present in the FLAG eluate, anti-HA flow-through and HA eluate.
(B) Proteins identified in immunopurified COP1 complex by mass spectrometry.
(C) Immunoblot analysis of proteins recovered after initial anti-FLAG immunoprecipitation and peptide elution as in (A). WCL, whole cell lysate; *, IgG; S.E., short
exposure; L.E., long exposure.
(D) Immunoblot analysis of 293FT cells transiently transfected with plasmids encoding the indicated 3xHA-tagged ETS2 variants and, where indicated, DET1 and
COP1 (WT or dominant-negative DE7). A plasmid encoding GFP was included as a transfection efficiency control.
(E) Immunoblot analysis of 293FT cells expressing a DOX-inducible COP1 shRNA and the indicated HA-tagged ETS2 variants. Cells were treated with or without
DOX (1 mg/ml) for 48 hr.
(F) In vitro ubiquitylation of 35S-ETS2 (WT or VPAA1&2) in the presence of recombinant E1 and E2 (UbcH5a) and immunopurified COP1.
(G) Anti-HA immunoblot analysis of ETS2-V5 (WT or VPAA1&2) that was immunoprecipitated under denaturing conditions from 293FT cells that were transiently
transfected with plasmids encoding the indicated proteins.
See also Figure S1.
Cancer Cell
Regulation of ETS1 by Src Family Kinases and COP1disrupt the interaction with COP1. Tomodel this, we first synthe-
sized biotinylated peptides corresponding to the potential COP
degron within ETS1. As this degron contains two potential serine
phosphorylation sites (residues 276 and 282), in addition to
the potential tyrosine phosphorylation site, we synthesized
eight peptides corresponding to every possible combination
of phosphorylation marks (Figure 3A). An additional peptide cor-
responding to the VPAA variant was included as a negative
control (Figure 3A). These peptides, immobilized on NeutrAvidin
agarose, were then used as affinity reagents to capture COP1
from 293FT cell extracts. COP1 bound, albeit weakly, to the
wild-type, unphosphorylated peptide (peptide 1), but not to the
VPAA peptide (peptide 9) (Figure 3A). Furthermore, as predicted,
phosphorylation of either serine residue enhanced the binding to224 Cancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc.COP1 (compare peptides 3, 5, and 7 to peptide 1). Importantly,
tyrosine phosphorylation decreased binding to COP1 when
combined with phosphorylation of the serine corresponding to
Ser282 (compare peptide 6 to 5 and 8 to 7). These results sup-
port that tyrosine phosphorylation decreases the binding affinity
of COP1 for ETS1.
To ask if this might also be true in cells, we stably infected
293FT cells with lentiviruses encoding HA-ETS1, or variants
thereof, under the control of the Ubc promoter and scored their
ability to capture endogenous COP1 in cells treated withMG132.
Very low levels of COP1 were recovered with either wild-type
(WT) COP1 or the VPAA (V280A/P281A) COP1 variant (Figure 3B,
lanes 2 and 3), suggesting that this level of recovery reflects
background noise in this assay or that ETS1 has a second,
Figure 2. Differential Regulation of ETS1 and ETS2 by COP1
(A) Schematics of ETS1 and ETS2.
(B) Alignments of COP1 degrons in ETS1 and ETS2 (C-terminal site) across species.
(C) In vitro ubiquitylation of 35S-ETS1 (WT or VPAA) in the presence of recombinant E1 and E2 (UbcH5a) and immunopurified COP1.
(D) Immunoblot analysis of anti-HA immunoprecipitates from 293FT cells producing the indicated HA-tagged ETS1 and ETS2 variants. Cells were treated with
10 mM MG132 6 hr before harvest.
(E) Immunoblot analysis of 293FT cells expressing a DOX-inducible COP1 shRNA and the indicated 3xHA-tagged ETS1 variants. Cells were treated with or
without DOX (1 mg/ml) for 48 hr.
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tyrosine 283 with phenylalanine (Y283F) dramatically enhanced
the recovery of COP1 (compare lane 4 to 2). Phosphorylation
of ETS1 Ser282 was confirmed using a phosphospecific anti-
body (Figure 3B). The signal obtained with this antibody was var-
iably slightly diminished when examining ETS1 mutants in which
Tyr283 was converted to phenylalanine, possibly due to slightly
lowered antibody binding affinity to the corresponding phospho-
peptides (Figure S2E).
We also tested ETS1 Y283F variants in which Ser276 and
Ser282 were changed to either aspartic acid or alanine in an
attempt to mimic phosphorylation or loss of phosphorylation,
respectively. As expected, converting these serines to alanine
abrogated COP1 binding by the Y283F variant (compare lane 6
to lane 4, lane 10 to lane 4, and lane 12 to lane 4). In contrast, re-
placing either Ser276 or Ser282 with aspartic acid enhanced
binding (compare lanes 7 and 8 to 4 and lanes 8, 9, and 11 to
lane 12), especially in combination (compare lane 8 to lane 12).
These results indicate that phosphorylation of ETS1 Ser276
and Ser282 promotes binding to COP1, while Tyr283 phosphor-
ylation decreases binding.
In keeping with these results, the Y283F substitution grossly
destabilized ETS1 relative to WT ETS1, unless Ser276 and
Ser282 were concurrently converted to alanine residues (Fig-
ure 3C). Moreover, induction of a COP1 shRNA in 293FT cells
stabilized the Y283F variant, but not WT ETS1 (Figure 3D). This
effect was specific because it was enhanced when both
Ser276 and Ser282 were converted to aspartic acid and elimi-nated when these two residues were converted to alanine (Fig-
ure 3D). Collectively, these results indicate that the differential
effects of COP1 on ETS1 and ETS2 in vivo relates to the ability
of ETS1 to be phosphorylated on Tyr283.
Regulation of ETS1 by Src Family Kinases
The sequence surrounding ETS1 Tyr283 resembles a Src family
kinase phosphorylation motif (Figure S3A), and Src can phos-
phorylate ETS1 on this site in vitro (Figures S3B and S3C). As
Src is a relatively promiscuous kinase in vitro, however, we pro-
ceeded to ask if Src can phosphorylate ETS1 in cells. In pilot ex-
periments we confirmed that70%of the ETS1 inMDA-MB-231
breast carcinoma cells, which have high Src activity (Sa´nchez-
Bailo´n et al., 2012), is tyrosine-phosphorylated (Figure S3D).
Next we treated MDA-MB-231 breast carcinoma cells with a
panel of small molecule kinase inhibitors and found that the
Src family kinase inhibitor dasatinib decreased ETS1 protein
levels compared to cells treated the Abl inhibitor imatinib, the
epidermal growth factor receptor (EGFR) family inhibitor lapati-
nib, or vehicle alone (Figure S3E). Inactivation of Src family
kinases by dasatinib was confirmed by the loss of Src autophos-
phorylation at Tyr416 (or its equivalent in the other Src family
kinases) and by decreased phosphorylation of the Src target
FAK (Figure S3E). Moreover, dasatinib had minimal effects on
ETS1 mRNA levels, suggesting that its effects on ETS1 were
posttranscriptional (Figure S3F).
Treatment of MDA-MB-231 cells with increasing amounts of
dasatinib decreased both ETS1 tyrosine phosphorylation andCancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc. 225
Figure 3. Phosphorylation of ETS1 Governs Its Recognition by COP1
(A) Immunoblot analysis of COP1 recovered from 293FT cell extracts after incubation with NeutraAvidin beads loaded with the indicated peptides.
(B) Immunoblot analysis of anti-HA immunoprecipitates from 293FT cells producing the indicated 3xHA-tagged ETS1 variants. Cells were treated with 10 mM
MG132 6 hr before harvest.
(C) Immunoblot analysis of 293FT cells expressing the indicated 3xHA-ETS1 variants after the addition of 100 mg/ml cycloheximide (CHX). Different exposure
times were used to normalize the 0 min band intensities for the different ETS1 variants.
(D) Immunoblot analysis of 293FT cells expressing a DOX-inducible COP1 shRNA and the indicated 3xHA-tagged ETS1 variants. Cells were treated with or
without DOX (1 mg/ml) for 48 hr.
See also Figure S2.
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tinib was prevented by proteasomal blockade (Figure 4A) or
depletion of COP1 with an inducible shRNA (Figure 4B).
Pulse-chase experiments confirmed that the effects of dasati-
nib reflected decreased ETS1 stability (Figure 4C). Moreover, the
effects of dasatinib were enhanced by ionomycin, which acti-
vates the CaMKII that can phosphorylate ETS1 Ser282 (Cowley
and Graves, 2000; Rabault and Ghysdael, 1994) (Figures 4C
and S3G).
Of note, inhibition of Src activity and the downregulation of
ETS1 were both detectable at nM concentrations of dasatinib
(Figures 4A and 4B), although the former was more pronounced
than the latter, possibly due to differences in the sensitivities of
the two assays and differences in the kinetics of Src inactivation
and ETS1 turnover (Figures 4C and 4D). In time course experi-
ments using cells treated with MG132, loss of ETS1 tyrosine
phosphorylation after treatment with dasatinib led to a reciprocal
increase in COP1 binding (Figures 4D and S3H).
To interrogate the importance of Tyr283 with respect to
the control of ETS1 by Src family kinases, MDA-MB-231 cells
were stably infected to produce ETS1-HA, ETS1 (VPAA)-HA, or226 Cancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc.ETS1 (Y283F)-HA under the control of the Ubc promoter. As
expected, treatment of these cells with dasatinib decreased
the tyrosine phosphorylation of WT ETS1 and the VPAA variant
(Figure 4E). In contrast, recognition of ETS1 (Y283F) with the
phosphotyrosine antibody under basal conditions was greatly
diminished compared to WT ETS1 and VPAA, and was not
further diminished by dasatinib (Figure 4E). Importantly, dasati-
nib also increased the binding of WT ETS to COP1 (Figure 4E).
This effect was specific because the VPAA variant did not bind
to COP1, while the Y283F variant constitutively bound with
COP1 (Figure 4E).
In a complementary set of experiments, MDA-MB-231 cells
were first infected to produce the DOX-inducible COP1 shRNA
and then superinfected to produce either WT ETS1-HA or ETS1
(Y283F) variants in which Ser276 and Ser282 were converted to
aspartic acid or alanine. As expected, WT ETS1 was minimally
affected by loss of COP1, presumably due to endogenous
Src family kinase activation (Figure 4F, compare lane 5 to 4),
and was downregulated with dasatinib (compare lane 6 to 4).
In contrast, ETS1 (Y283F) was sensitive to COP1 loss (Fig-
ure 4F, compare lane 8 to 7) and no longer stabilized by
Figure 4. Dasatinib Downregulates ETS1
(A and B) Immunoblot analysis of anti-ETS1 immunoprecipitates or whole cell extracts of MDA-MB-231 cells expressing a DOX-inducible COP1 shRNA treated
with increased amounts of dasatinib for 8 hr with or without pretreatment of MG132 (10 mM) for 2 hr (A) or Dox (1 mg/ml) for 48 hr (B).
(C) 35S Pulse-chase analysis of ETS1 recovered from MDA-MB-231 cells pretreated with dasatinib (10 mM) for 3 hr and/or ionomycin (2 mM) for 0.5 hr. MDA-MB-
231 cells treated with DMSO were used as a control (CNTL).
(D) Immunoblot analysis of anti-ETS1 immunoprecipitates or whole cell extracts of MDA-MB-231 cells at the indicated time points after addition of dasatinib
(10 mM). Where indicated, cells were pretreated with MG132 (10 mM) for 2 hr.
(E) Immunoblot analysis of anti-HA immunoprecipitates or whole cell extracts of MDA-MB-231 cells producing the indicated 3xHA-tagged ETS1 variants pre-
treated with MG132 (10 mM) for 2 hr and, where indicated, with dasatinib (10 mM), for an additional 8 hr.
(F) Immunoblot analysis ofMDA-MB-231 cells expressing aDOX-inducible COP1 shRNA and the indicated HA-tagged ETS1 variants.Where indicated, cells were
pretreated with Dox (1 mg/ml) for 48 hr and dasatinib (10 mM) for an additional 8 hr. Dotted line indicates where irrelevant lanes were removed from the blot image.
See also Figure S3.
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dependent turnover of ETS1 (Y283F) was enhanced by phos-
phomimetic mutations at Ser276 and Ser282 and completely
abrogated by replacement of these two residues with alanines
(Figure 4F).
To identify the relevant target(s) of dasatinib, we next infected
MDA-MB-231 cells with lentiviral vectors stably expressing
shRNAs against either Src or the Src family kinases Fyn,
Lyn, and Yes (Figure 5A). There were two effective shRNAs
that were interrogated per gene. None of these four kinases,
when downregulated in isolation, significantly altered ETS1
levels and FAK phosphorylation (Figure 5A). However, combined
downregulation of Src and Yes, but not Src with Fyn or Lyn,
dramatically lowered ETS1 tyrosine phosphorylation, ETS1
levels, and FAK phosphorylation (Figures 5B, S4A, and S4B).
Moreover, expression of dasatinib-resistant versions of Src or
Yes, but not their WT counterparts, restored ETS1 protein levels
in dasatinib-treated cells without affecting ETS1 mRNA levels
(Figures 5C, 5D, and S3F). These results suggest that Src and
Yes are redundant with respect to regulation of ETS1 stability.Role for Src-Dependent Accumulation of ETS1 in Triple
Negative Breast Cancer
Both Src and ETS1 have been implicated as breast cancer onco-
genes (Bendinelli et al., 2011; Bosman et al., 2010; Buggy et al.,
2004; Charafe-Jauffret et al., 2006; Lincoln and Bove, 2005;
Mayer and Krop, 2010; Myers et al., 2005; Mylona et al., 2006;
Sa´nchez-Bailo´n et al., 2012; Span et al., 2002; Vetter et al.,
2005; Zhang et al., 2011). We next surveyed ETS1 protein levels
and Src family kinase activity in a panel of breast cancer cell
lines. ETS1 protein levels were highest in triple negative breast
cancer lines and correlated well with Src family kinase (SFK) acti-
vation, as determined using an antibody specific for SFKs phos-
phorylated at the tyrosine equivalent to Src 416 (Figures 5E and
S4C). Moreover, ETS1 tyrosine phosphorylation and ETS1 levels
fell dramatically in triple negative breast cancer cells treated with
dasatinib (Figures 5F, S4D, and S4E).
Protein kinase C alpha (PKCa) also reportedly regulates ETS1
levels (Lindemann et al., 2003; Vetter et al., 2005). Levels of acti-
vated PKCa did not, however, correlate with ETS1 levels across
the breast cancer lines depicted in Figure 5E (Figure S4F) andCancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc. 227
Figure 5. Src and Yes Redundantly Control ETS1 Stability
(A and B) Immunoblot analysis of MDA-MB-231 cells expressing the indicated shRNAs.
(C and D) Immunoblot analysis of MDA-MB-231 cells expressing the indicated Src (C) or Yes (D) variants and treated, where indicated, with dasatinib.
(E and F) Immunoblot of the indicated breast cancer cell lines. Basal A subtype (BaA); Basal B subtype (BaB). Dasatinib (1 mM) was added for 8 hr where indicated
in (F). S.E., short exposure; L.E., long exposure.
See also Figure S4.
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shRNAs did not affect ETS1 levels (Figure S4G).
To ask if ETS1 plays a role in Src-dependent transformation,
we infected MCF10A immortalized mammary epithelial cells
with a lentivirus encoding a v-Src-estrogen receptor (ER) fusion
protein (Hirsch et al., 2009; Iliopoulos et al., 2009; Reginato
et al., 2005), which can be activated with tamoxifen, and then
superinfected them with lentiviruses encoding one of three
different DOX-inducible ETS1 shRNAs or a control shRNA
(Figure 6A). As expected, administration of tamoxifen increased
Src activity, manifest as increased phosphorylation of the
downstream target FAK (Figure 6A), and was associated with
increased ETS1 levels and increased soft agar growth, except
in those cells producing any one of three independent ETS1
shRNAs (Figures 6A and 6B). These shRNA effects were on-
target because they could be rescued by concurrent expression
of an ETS1 cDNA that was engineered to be shRNA-resistant
(Figures S5A and S5B).
To ask if phosphorylation of ETS1 at Tyr283 is required for
Src to promote soft agar growth by MCF10A cells, we gener-
ated MCF10A-v-SRC-ER cells stably expressing either an
ETS1 shRNA or a control shRNA (Figures 6C and 6D). These cells
were then infected with viruses encoding ETS1 shRNA-resistant
versions of WT ETS1 or ETS1 variants bearing the Y283F muta-228 Cancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc.tion, VPAA mutation, or both mutations. As expected, tamoxifen
treatment of cells increased the level of exogenousWTETS1, but
not the Y283F variant, whereas the VPAA variants were constitu-
tively stable (Figure 6C). Moreover, WT ETS1 rescued v-Src
mediated transformation in MCF10A cells in which endogenous
ETS1 was first depleted by the ETS1 shRNA, while the Y283F
variant did not unless it was rendered stable by a concurrent
VPAA mutation (Figures 6D and 6E). Therefore promotion of
breast cancer soft agar growth, a hallmark of transformation,
by SFKs requires that they stabilize ETS1.
In keeping with the results obtained in MCF10A cells, down-
regulation of ETS1 using two independent shRNAs in MDA-
MB-231 cells significantly decreased soft agar growth, without
affecting cell proliferation in vitro (Figures 7A, 7B, and S6A). In
a complementary set of experiments, we engineered MDA-
MB-231 breast cancer cells to produce firefly luciferase and
then infected them to produce an shRNA against GFP or one
of two shRNAs against ETS1 (shRNA number 2 or 3). These cells
were then injected into the mammary fat pads of immunocom-
promised mice and allowed to form orthotopic tumors. Downre-
gulation of ETS1 with either shRNA impaired tumor growth
relative to cells expressing the GFP shRNA, as determined by
serial bioluminescent imaging and tumor mass at necropsy,
unless cells also expressed an shRNA-resistant ETS1 cDNA
Figure 6. Role of Src and ETS1 in Mammary Transformation
(A and B) Immunoblot analysis (A) and soft agar assay (B) of MCF10A cells expressing a v-Src-ER fusion protein and the indicated DOX-inducible shRNAs. Cells
were grown in the presence of DOX (1 mg/ml). 4-OH-tamoxifen (TAM, 1 mg/ml) was also addedwhere indicated. Parental MCF10Awere included in (A) as a control.
Scale bars, 0.5 mm.
(C, D, and E) Immunoblot analysis (C and D) and soft agar assay (E) of MCF10A-v-Src-ER cells stably expressing control shRNA (shControl) or shRNA against
ETS1 (shETS1-3) and indicated shRNA-resistant (res) ETS1 cDNAs. Cells were treated with vehicle or 4-OH-tamoxifen (TAM, 1 mg/ml) for 12 hr where indicated.
Scale bars, 0.5 mm. Representative images shown in (B) and (E) are from three biological replicates.
See also Figure S5.
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Regulation of ETS1 by Src Family Kinases and COP1(Figures 7C–7F and S6B–S6J). Therefore ETS1 promotes breast
transformation in vitro and in vivo.
Next, we measured ETS1 protein levels and Src phosphoryla-
tion in human breast tumors by immunohistochemistry (Figures
7G and 7H). In 222 cores derived from 86 patients with triple
negative breast cancer who underwent surgery for localized
breast cancer, we found a significant correlation between
ETS1 protein level and Src phosphorylation. There were 31 (75
cores) out of 33 tumors (82 cores) that had high Src activity, as
determined by phosphorylation of Src tyrosine residue 416,
and also had high ETS1 protein levels. Conversely, 18 (43 cores)
out of 53 tumors (140 cores) that had low or undetectable Src ac-
tivity also had low levels of ETS1 (Figure 7I; Table S1) (p < 0.001).
Collectively, these results support that Src activation is sufficient
to promote the stabilization of ETS1, which contributes to breast
cancer pathogenesis. The finding that some breast tumors withhigh ETS1 nonetheless had low levels of Src tyrosine 416
phosphorylation could reflect technical challenges measuring
phosphoepitopes by immunohistochemistry or could signal the
existence of alternative means of inducing ETS1.
DISCUSSION
We found that the stabilities of ETS1 and ETS2, like those of the
ETS family members ETV1, ETV4, and ETV5 (Vitari et al., 2011),
are under the control of the COP1 ubiquitin ligase, thus expand-
ing the linkage between the ETS family of oncogenic tran-
scription factors and the COP1 tumor suppressor protein.
COP1 inactivation has been linked to multiple cancers including
human prostate cancer, which is often linked to deregulation
of ETS family members (Clark and Cooper, 2009; Kumar-Sinha
et al., 2008; Marine, 2012).Cancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc. 229
Figure 7. ETS1 Promotes Tumor Growth in Human Triple Negative Breast Cancer
(A and B) Immunoblot analysis (A) and soft agar assay (B) of MDA-MB-231 cells stably expressing shRNAs against GFP or ETS1 (shRNA 2 or 3) and, where
indicated, an mRNA encoding venus fluorescent protein (Venus) or an shRNA-resistant (for shRNA 3) mRNA encoding ETS1 (ETS1res). Representative images in
(B) are from three biological replicates.
(C and D) Representative bioluminescent images of mice orthotopically injected with MDA-MB-231 cells stably expressing firefly luciferase cDNA and the
indicated shRNAs (C) and quantification of shEST1-3/shGFP signal ratios at the indicated time (D, n = 5). Error bar represents SEM.
(E and F) Representative appearance of tumors (E) and mean tumor mass (F) at necropsy. Error bar indicates SEM.
(G and H) Representative images of breast cancer tumors with high (G) or low (H) levels of ETS1 and phospho-Tyr416 Src detected by immunohistochemistry.
Red solid box in (a) and (b) are magnified in (c) and (d), respectively. Scale bars (a) and (b) represent 100 mM; Scale bars (c) and (d) represent 20 mM.
(I) The classification of tumor cores based upon the level of ETS1 and phospho-Tyr416 Src.
See also Figure S6 and Table S1.
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Regulation of ETS1 by Src Family Kinases and COP1Notably, the COP1-binding degrons in ETS1 and ETS2, in
contrast to ETV1, ETV4, and ETV5, contain serine or threonine
residues in positions that are normally occupied by aspartic
acid or glutamic acid in the COP1 substrates that have been
well documented to date. This suggests that the number of po-
tential COP1 substrates, based on primary sequence homology,
is larger than would have been previously predicted and that
some of these substrates will require priming phosphorylation
events in order to generate the negative charges that would
otherwise be provided by aspartic acid or glutamic acid. It will
be important to determine which amino acids in the spacer
element of this expanded COP1-binding motif {[DEST]-X (2,3)-
V-P-[DEST]} are permissive for recognition by COP1, as well as
the importance of local secondary structure.230 Cancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc.There are many examples of substrates that must be phos-
phorylated in order to be recognized by their cognate ubiquitin li-
gases. Examples include p27, beta-catenin, and cyclin E, which
are recognized by SKP2SCF, bTRCPSCF, and Fbw7SCF, respectively
(Deshaies, 1999). In the case of ETS1, priming phosphorylation
appears to be accomplished by calcium and calmodulin-depen-
dent kinases (CaM kinases). For example, ETS1 is rapidly phos-
phorylated by these enzymes upon T-cell activation (Bhat et al.,
1990). This leads to decreased ETS1 protein levels, as well as
conformational changes that alter the dependence of ETS1 on
neighboring transcription factors (Bhat et al., 1990; Cowley and
Graves, 2000; Pognonec et al., 1988). Thus both the duration
and the quality of the ETS1 response are potentially coregulated
by CaM kinases following T-cell activation.
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Regulation of ETS1 by Src Family Kinases and COP1We also discovered that ETS1, in addition to requiring priming
phosphorylation, contains a tyrosine residue that inhibits COP1
recruitment when phosphorylated by SFKs. Src and Yes appear,
based on our studies, to be the SFKs that control ETS1 in breast
cancer cells, but it is possible that other Src family members as-
sume this role in other contexts. Thus the COP1 degron within
ETS1, the cellular homolog of v-ETS and a founding member
of the mammalian ETS family, integrates both positively and
negatively acting kinase signals. A search of the PROSITE data-
base revealed 126 human proteins containing the sequence
[DEST]-X (2,3)-V-P-[DEST]-Y, suggesting that regulation by tyro-
sine phosphorylation might extend to other COP1 substrates
(our unpublished data). Included among these 126 proteins are
the ETS family members ETV1 and ETV6 (also called TEL), the
COP1-associated proteins CUL4 and TRIB1, and several tyro-
sine phosphatases. Preliminary experiments suggest that the
motifs in ETV1 and TRIB1 can, as synthetic peptides, bind to
COP1, and that their binding is diminished by tyrosine phos-
phorylation (our unpublished data). Notably, some of the 126
proteins contain COP1 binding motifs that also conform with
known phosphorylation motifs including PTPRG (Abl kinase),
CNN2 (PGFRBkinase), MPP7 (PDGFR and Src kinases),
KHDR2 (Fgr kinase), ILRL1 (EGFR kinase), and ATAD2 (EGFR,
Fgr, and PDGFR kinases) (our unpublished data).
The paradigm of degrons integrating positively and negatively
acting signals probably extends to other ubiquitin ligase-
substrate pairs aswell. For example, YAP1 and IkBa both contain
degrons that,whenphosphorylated, are recognizedby bTRCPSCF.
Phosphorylation of adjacent tyrosine residues, however, results
in their stabilization, presumably by blocking the recruitment
of bTRCPSCF, although this has not yet been formally proven
(Levy et al., 2008; Singh et al., 1996; Zhao et al., 2010).
The knowledge that priming phosphorylation of the COP1
degron within ETS1 is antagonized by phosphorylation of a
neighboring tyrosine residue by SFKs suggests that some of
the oncogenic activity of these kinases relates to activation of
ETS target genes. In support of this view, earlier studies showed
that increased Src activity and increased ETS1 are both features
of triple negative breast cancers (Buggy et al., 2004; Charafe-
Jauffret et al., 2006; Elsberger et al., 2009; Finn et al., 2007,
2011; Mylona et al., 2006; Tryfonopoulos et al., 2011). Our
work suggests that these two observations are linked. We found
that ETS1 levels correlate with Src activity in mammary carci-
noma cell lines, that inhibiting Src downregulates ETS1, and
that elimination of ETS1 blunts Src’s ability to promotemammary
proliferation in soft agar. Interestingly, ETS1 has been linked
to breast cancer pathogenesis before, where it is associated
with a poor prognosis (Bosman et al., 2010; Myers et al., 2005;
Mylona et al., 2006; Span et al., 2002; Zhang et al., 2011).
Dasatinib inhibits the proliferation of breast cancer cell lines,
especially triple negative breast cancer lines (Finn et al., 2007;
Huang et al., 2007; Kurebayashi et al., 2010; Lehmann et al.,
2011; Tryfonopoulos et al., 2011). Moreover, breast cancer lines
with the highest basal levels of ETS1 tended to be the most sen-
sitive to dasatinib in these earlier reports (for example, compare
Figure 5E here to Table 1 in Finn et al., 2007). Nonetheless, we
have so far been unable to block the antiproliferative effects of
dasatinib in vitro by eliminating COP1 or by expressing stabilized
versions of ETS1 (data not shown). This suggests that the anti-proliferative effects of dasatinib in vitro involve at least one Src
target other than ETS1. In addition, Src inhibitors have thus far
exhibited very modest activity in breast cancer patients (Herold
et al., 2011; Mayer et al., 2011). This might reflect a failure to
adequately enrich for patients whose tumors have activated
Src or to achieve adequate target inhibition in vivo. In this regard,
ETS1 might eventually serve as a predictive biomarker, as
a pharmacodynamic biomarker, or perhaps both. It is also
possible that failure to observe overt regressions of established
tumors in breast cancer patients treated with dasatinib reflects a
greater role for Src (and ETS1) in tumor invasion and metastasis
than in tumor maintenance. ETS1 directly regulates a number of
genes involved in invasion and metastasis, such as MMPs and
integrins, and might thereby amplify the effects of Src-depen-
dent phosphorylation of substrates such as FAK and TKS5 that
also affect these processes (Hahne et al., 2005; Murphy and
Courtneidge, 2011; Zhao and Guan, 2009).
The interactions of enzymes with their substrates are often
transient in nature, precluding detection in coimmunoprecipita-
tion assays. Moreover, polyubiquitylation at the hands of ligases
such as the COP1 complex causes substrate destruction. We
were therefore surprised that we could readily detect complexes
containing COP1 and its substrates by coimmunoprecipitation
from cells that had not been treated with drugs intended to block
enzyme function or protein turnover. This raises the possibility
that COP1 activity is, itself, subject to regulation that dictates
whether bound substrates are efficiently polyubiquitylated. If
this is true, this would imply that upstream signals impinge
upon both the COP1 complex and its substrates.
EXPERIMENTAL PROCEDURES
Cell Culture
293FT human embryonic kidney (Invitrogen), HCT116 (ATCC), MDA-MB-231-
LUC (a kind gift from Dr. Kimberly Briggs), and ATCC breast cancer cell
lines MCF-7, ZR-75-1, T47D, BT-474, MDA-MB-453, SK-BR-3, BT-20, BT-
549, MDA-MB-157, MDA-MB-231, MDA-MB-436, MDA-MB-468, HCC70,
HCC1143, HCC1806, and HCC1937 were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/
ml penicillin, and 100 mg/ml streptomycin. MCF10A-v-SRC-ER cell line was
kindly provided by Dr. Dimitrios Iliopoulos (University of California at Los
Angeles). MCF10A (ATCC) and MCF10A-v-Src-ER cells were maintained in
DMEM/F12 growth medium containing 5% charcoal stripped horse serum,
100 U/ml penicillin, 100 mg/ml streptomycin, 20 ng/ml EGF, 0.5 mg/ml hydro-
cortisone, 100 ng/ml cholera toxin, and 10 mg/ml insulin. For v-Src acute acti-
vation, MCF10A and MCF10A-v-Src-ER cells were grown in assay medium
[DMEM/F12 medium containing 2% charcoal-stripped horse serum, 100 U/
ml penicillin, 100 mg/ml streptomycin, 0.5 mg/ml hydrocortisone, 100 ng/ml
cholera toxin, and 10 mg/ml insulin] for 48 hr, and then treated with 1 mg/ml
4-OH-tamoxifen for additional 6 hr. Stable cell lines were established by lenti-
viral infection followed by growth in media containing appropriate antibiotics
(1 mg/ml puromycin, 20 mg/ml blasticidin, 800 ng/ml neomycin, or 500 mg/ml
hygromycin).
Orthotopic Tumor Growth Assay
All animal experiments complied with NIH guidelines and were approved by
Dana-Farber Cancer Institute Animal Care and Use Committee. For orthotopic
tumor growth assay, 5 3 105 viable MDA-MB-231-LUC tumor cells were re-
suspended in 40 ml growth factor-reduced Matrigel (BD Biosciences) and in-
jected into the #4 and #9 mammary glands of 8-week-old female NOD scid
gamma mice Jackson Lab, Bar Harbor, Maine). Mice were sacrificed 8 weeks
later to determine the tumor size. For weekly bioluminescence imaging, mice
were injected intraperitoneally with 150 mg.g-1 D-luciferin in PBS. After 5 min,Cancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc. 231
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Regulation of ETS1 by Src Family Kinases and COP1tumor burden was measured in an in vivo imaging system and quantified using
the Living Image software (Xenogen). Results are presented as means (of total
photon flux) ± SEM.
Immunohistochemistry
The breast cancer tissue microarray containing 89 triple negative tumors
(negative for estrogen receptor, progesterone receptor, and HER2) was con-
structed with tissues obtained from patients who provided written informed
consent under Dana Farber Cancer Institute Institutional Review Board proto-
col 93-085. Each tumor sample was represented by three tissue microarray
cores that, when possible, were taken from different areas of the same tumor.
Immunohistochemical staining of ETS1 and phospho-Src was performed on
4 mm sections of the tissue microarray (TMA); using the Bond Refine Detection
System following the manufacturer’s protocols on the Leica Bond III auto-
mated immunostainer. The sections were automatically deparaffinized, anti-
gen retrieval was done with EDTA buffer (pH 9.0) and processed for 20 min.
The slides were incubated with the antibody against ETS-1 (1G11, Mouse
monoclonal, ab10936, Abcam) at a dilution of 1:100, or phospho-Src
(Tyr416, Rabbit polyclonal, #2101, Cell Signal Technology) at a dilution of
1:50 for 60 min, respectively. The sections were then treated according to
the streptavidin-biotin-peroxidase complex method (Bond Polymer Refine
Detection, Leica Microsystems) with diaminobenzidine as a chromogen and
counterstained with hematoxylin. Tonsil tissue was used as positive controls
for ETS-1, and testis tissue was used as positive controls for phospho-Src,
respectively. Omission of the primary antibody was used as a negative control.
To evaluate immunohistochemistry expression of ETS1 and pSrc on the
TMA, we utilized a semiquantitative scoring system, whereby stain intensity
and percentage tumor cell positivity were assessed by a pathologist. For
each core, we assigned the percentage score of 0 (<5% tumor cell positivity),
1 (R5% and <50% tumor cell positivity), 2 (R50% tumor cell positivity), and
the intensity score of 0 for negative, 1 for weak or moderate staining, and 2
for strong staining (Merritt et al., 2008). ETS1 (cytosol), ETS1 (nuclear), pSrc
(cytosol), and pSrc (membrane) were scored separately. Last, for ETS1 or
pSrc, the overall staining intensity and percentage positivity scores generated
an 8-point score. There were three cases TN33, TN52, and TN59 that were
excluded from data analysis due to no or too few tumor cells, or because all
three cores were missing after sectioning. In order to correlate ETS1 and
pSrc expression, we binned the individual scores for eachmarker and grouped
them based on high and low expression levels. Statistical analysis was carried
out using SPSS V.13.0. The Spearman rank correlation was used to investigate
the correlation of the protein expression between ETS1 and phospho-Src.
p values less than 0.05 were considered statistically significant.
Antibodies
Anti-COP1 antibody (A300-894A), anti-ETS1 antibody (A303-501A), anti-ZEB2
antibody (A302-474A), anti-V5 antibody (A190-120A), and horseradish perox-
idase (HRP) conjugated anti-rabbit secondary antibody (ReliaBLOT, WB120)
were purchased from Bethyl. Anti-phospho-ETS1 (S282) antibody (44-1109),
anti-phospho-ETS1 (S282/S285) antibody (44-1111), and anti-V5 (2F11F7)
mousemonoclonal antibody (mAb) (37-7500) were purchased from Invitrogen.
Anti-ETS2 antibody (SC-351), anti-GFP antibody (SC-9996), anti-HA antibody
(SC-805), and anti-ERa antibody (SC-543) were purchased from Santa Cruz.
Anti-CUL4A antibody (2699), anti-DDB1 antibody (5428S), anti-c-Jun (60A8)
rabbit mAb (9165), anti-phospho-FAK (Tyr576/577) antibody (3281), anti-
FAK antibody (3285), anti-phospho-Src Family (Tyr416) antibody (2101S),
anti-Src (32G6) rabbit mAb (2123), anti-Yes antibody (3201), anti-Fyn antibody
(4023), anti-Lyn (C13F9) rabbit mAb (2796), anti-PKCa antibody (2056), anti-
phospho-PKCa/b II (Thr638/641) antibody (9375), anti-PKCd (D10E2) rabbit
mAb (9616), anti-phospho-PKCd (Thr505) antibody (9374), anti-E-Cadherin
(24E10) rabbit mAb (3195), anti-N-Cadherin antibody (4061), anti-Vimentin
(D21H3) rabbit mAb (5741), anti-Claudin-1 antibody (4933), anti-b-Catenin
(D10A8) rabbit mAb (8480), anti-ZO-1 (D7D12) rabbit mAb (8193), anti-Snail
(C15D3) rabbit mAb (3879), anti-Slug (C19G7) rabbit mAb (9585), anti-ZEB1
(D80D3) rabbit mAb (3396), Phospho-Tyrosine mouse mAb (P-Tyr-100) (HRP
Conjugate) (5465), anti-HA (6E2) mouse mAb (HRP Conjugate) (2999), anti-
Myc (9B11) mouse mAb (2276), and anti-Myc (71D10) Rabbit mAb (2278)
were purchased from Cell Signaling. Anti-Twist antibody (ARP37997_T100)
was purchased from Aviva. Anti-HA (16B12) Mouse mAb (MMS-101P) was232 Cancer Cell 26, 222–234, August 11, 2014 ª2014 Elsevier Inc.purchased from Covance. Rabbit anti-FLAG antibody (F2425), mouse anti-
FLAG M2 antibody (F-3165), anti-FLAG M2 (HRP conjugate) (A8592), and
anti-Vinculin antibody (V9131) were purchased from Sigma. Anti-ETV5
(7C10) mouse mAb (H00002119-M02) was purchased from Abnova.
Anti-DET1 (4123) mouse mAb and anti-COP1 (4466) mouse mAb were kindly
provided by Dr. Vishva Dixit (Genentech). Peroxidase-conjugated goat anti-
mouse secondary antibody (31430) and peroxidase conjugated goat anti-rab-
bit secondary antibody (31460) were purchased from Thermo.
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